Effects of a monoclonal anti-αvβ3 integrin antibody on blood vessels - A pharmacodynamic study

Investigational New Drugs

Volumn 25, Issue 1, 2007, Pages 49-55

  Zhang, Dahua ^a   Pier, Thomas ^a   McNeel, Douglas G ^b   Wilding, George ^b   Friedl, Andreas ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Angiogenesis; Focal adhesion kinase; Integrin; Phase I trial; Wound healing

Indexed keywords

FOCAL ADHESION KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ALPHAVBETA3 INTEGRIN; MONOCLONAL ANTIBODY LM 609; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ADULT; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOFLUORESCENCE TEST; LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PUNCH BIOPSY; SKIN BIOPSY; SOLID TUMOR; TUMOR BIOPSY; WOUND ASSESSMENT;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOOD VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIUM, VASCULAR; FLUORESCENT ANTIBODY TECHNIQUE; FOCAL ADHESION KINASE 1; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INFUSIONS, INTRAVENOUS; INTEGRIN ALPHAVBETA3; LYMPHOMA; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SKIN; TIME FACTORS;

EID: 33750453376     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9013-8     Document Type: Article

References (24)

1. Brooks PC, Clark RA, Cheresh DA (1994) Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569-571
2. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815-1822
3. Patel SR, Jenkins J, Papadopolous N, Burgess MA, Plager C, Gutterman J, Benjamin RS (2001) Pilot study of vitaxin - an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer 92:1347-1348
4. Gutheil JC, Campbell TN, Pierce PR, Watkins JD, Huse WD, Bodkin DJ, Cheresh DA (2000) Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res 6:3056-3061
5. Wu H, Beuerlein G, Nie Y, Smith H, Lee BA, Hensler M, Huse WD, Watkins JD (1998) Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. Proc Natl Acad Sci USA 95:6037-6042
6. McNeel DG, Eickhoff J, Lee FT, King DM, Alberti D, Thomas JP, Friedl A, Kolesar J, Marnocha R, Volkman J, Zhang J, Hammershaimb L, Zwiebel JA, Wilding G (2005) Phase I trial of a monoclonal antibody specific for {alpha}v{beta}3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin Cancer Res 11:7851-7860
7. Lockhart AC, Braun RD, Yu D, Ross JR, Dewhirst MW, Humphrey JS, Thompson S, Williams KM, Klitzman B, Yuan F, Grichnik JM, Proia AD, Conway DA, Hurwitz HI (2003) Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res 9:586-593
8. Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, Chappell R, Neider R, Sebree LA, Friedl A (2001) Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 7:3366-3374
9. Mitra SK, Hanson DA, Schlaepfer DD (2005) Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 6:56-68
10. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164
11. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Cullere M, Ross FP, Coller BS, Teitelbaum S, Hynes RO (1999) Beta3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest 103:229-238
12. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM (2002) Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 8:27-34
13. Bader BL, Rayburn H, Crowley D, Hynes RO (1998) Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95:507-519
14. Hynes RO (2002) A reevaluation of integrins as regulators of angiogenesis. Nat Med 8:918-921
15. Cheresh DA, Stupack DG (2002) Integrin-mediated death: an explanation of the integrin-knockout phenotype? Nat Med 8:193-194
16. Carmeliet P (2002) Integrin indecision. Nat Med 8:14-16
17. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD (2000) FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2:249-256
18. Parsons JT (2003) Focal adhesion kinase: the first ten years. J Cell Sci 116:1409-1416
19. Renshaw MW, Price LS, Schwartz MA (1999) Focal adhesion kinase mediates the integrin signaling requirement for growth factor activation of MAP kinase. J Cell Biol 147:611-618
20. Aplin AE, Short SM, Juliano RL (1999) Anchorage-dependent regulation of the mitogen-activated protein kinase cascade by growth factors is supported by a variety of integrin alpha chains. J Biol Chem 274:31223-31228
21. Ilic D, Furuta Y, Kanazawa S, Takeda N, Sobue K, Nakatsuji N, Nomura S, Fujimoto J, Okada M, Yamamoto T (1995) Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377:539-544
22. Ilic D, Kovacic B, McDonagh S, Jin F, Baumbusch C, Gardner DG, Damsky CH (2003) Focal adhesion kinase is required for blood vessel morphogenesis. Circ Res 92:300-307
23. Shen TL, Park AY, Alcaraz A, Peng X, Jang I, Koni P, Flavell RA, Gu H, Guan JL (2005) Conditional knockout of focal adhesion kinase in endothelial cells reveals its role in angiogenesis and vascular development in late embryogenesis. J Cell Biol 169:941-952
24. Miles KA, Charnsangavej C, Lee FT, Fishman EK, Horton K, Lee TY (2000) Application of CT in the investigation of angiogenesis in oncology. Acad Radiol 7:840-850